- Home
- Slides
- Home
- Tools and Resources
- Research Summaries for Consumers, Clinicians, and Policymakers
- Search for Research Summaries, Reviews, and Reports
- Research Available for Comment
- Submit a Suggestion for Research
- Submit Scientific Information Packets
- Comparative Effectiveness Research Grant and ARRA Awards
- News and Announcements
- What Is Comparative Effectiveness Research
- Who Is Involved in the Effective Health Care Program
- What Is the Effective Health Care Program
Slides
Slides: 1–6 of 6
Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Clinically Significant Outcomes of Interest (1 of 2)
Keywords: Juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | physician global assessment | ACR Ped | parent global assessment | active joint count | erythrocyte sedimentation rate | ESR | radiographic
Summary of Study Characteristics Evaluated in the Effectiveness Review: PICOTS
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | NSAIDs | intra-articular corticosteroids | DMARDs | disease status | health status | inflammation | radiographic progression | PICOTs
Evaluating JIA Assessment Instruments (2 of 3)
Keywords: ACR Pediatric | anti-rheumatic | antirheumatic | assessment | biologic DMARD | disease-modifying | DMARDs | flare | JCA | JIA | JRA | juvenile rheumatoid arthritis | non-biologic DMARD | nonbiologic DMARD | remission | rheumatic | TNF-alpha blockers | juvenile idiopathic arthritis
Evaluating JIA Assessment Instruments: Conclusions (2 of 2)
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | assessment | validity | reliability | responsiveness
Clinically Significant Outcomes of Interest in the Comparative Effectiveness Review
Presentation: Drug Therapy for Rheumatoid Arthritis in Adults
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | oral | disease activity | ACR | radiographic evidence of progression | functional capacity | HAQ | quality of life | SF-36 | DAS
Your slide tray is being processed.